中华耳鼻咽喉头颈外科杂志
中華耳鼻嚥喉頭頸外科雜誌
중화이비인후두경외과잡지
CHINESE JOURNAL OF OTORHINOLARYNGOLOGY HEAD AND NECK SURGERY
2008年
3期
218-223
,共6页
杨安奎%刘天润%郭翔%齐国隆%陈福进%郭朱明%张诠%曾宗渊%陈伟超%李秋梨
楊安奎%劉天潤%郭翔%齊國隆%陳福進%郭硃明%張詮%曾宗淵%陳偉超%李鞦梨
양안규%류천윤%곽상%제국륭%진복진%곽주명%장전%증종연%진위초%리추리
鼻咽肿瘤%药物疗法,联合%放射疗法%Meta分析
鼻嚥腫瘤%藥物療法,聯閤%放射療法%Meta分析
비인종류%약물요법,연합%방사요법%Meta분석
Nasopharyngeal neoplasms%Drug therapy,combination%Radiotherapy%Metaanalysis
目的 通过与单纯放疗相比较,对同步放化疗在中国大陆局部晚期鼻咽癌中的临床应用价值进行系统评价.方法 检索中国生物医学文献数据库、Cochrane图书馆、MEDLINE光盘数据库、EMBASE光盘数据库,鉴定有关随机对照试验,采用RevMan软件进行分析.结果 按纳入标准筛选,共纳入18个临床研究的1993例患者纳入研究,涉及同步放化疗能与单纯放疗在晚期鼻咽癌患者的生存率和远处转移率等方面的比较.同步放化疗组和单纯放疗组3年生存率分别为68.47%和56.38%,5年生存率分别为51.91%和41.09%;同步放化疗组和单纯放疗组的远处转移率分别为26.19%和38.71%.与单纯放疗相比,同步放化疗可以将患者的3年和5年生存率分别提高12%和11%;同步放化疗组比单纯放疗组降低远处转移率12%.结论 与单纯放疗相比,同步放化疗可能提高晚期鼻咽癌患者的生存率,降低远处转移率.
目的 通過與單純放療相比較,對同步放化療在中國大陸跼部晚期鼻嚥癌中的臨床應用價值進行繫統評價.方法 檢索中國生物醫學文獻數據庫、Cochrane圖書館、MEDLINE光盤數據庫、EMBASE光盤數據庫,鑒定有關隨機對照試驗,採用RevMan軟件進行分析.結果 按納入標準篩選,共納入18箇臨床研究的1993例患者納入研究,涉及同步放化療能與單純放療在晚期鼻嚥癌患者的生存率和遠處轉移率等方麵的比較.同步放化療組和單純放療組3年生存率分彆為68.47%和56.38%,5年生存率分彆為51.91%和41.09%;同步放化療組和單純放療組的遠處轉移率分彆為26.19%和38.71%.與單純放療相比,同步放化療可以將患者的3年和5年生存率分彆提高12%和11%;同步放化療組比單純放療組降低遠處轉移率12%.結論 與單純放療相比,同步放化療可能提高晚期鼻嚥癌患者的生存率,降低遠處轉移率.
목적 통과여단순방료상비교,대동보방화료재중국대륙국부만기비인암중적림상응용개치진행계통평개.방법 검색중국생물의학문헌수거고、Cochrane도서관、MEDLINE광반수거고、EMBASE광반수거고,감정유관수궤대조시험,채용RevMan연건진행분석.결과 안납입표준사선,공납입18개림상연구적1993례환자납입연구,섭급동보방화료능여단순방료재만기비인암환자적생존솔화원처전이솔등방면적비교.동보방화료조화단순방료조3년생존솔분별위68.47%화56.38%,5년생존솔분별위51.91%화41.09%;동보방화료조화단순방료조적원처전이솔분별위26.19%화38.71%.여단순방료상비,동보방화료가이장환자적3년화5년생존솔분별제고12%화11%;동보방화료조비단순방료조강저원처전이솔12%.결론 여단순방료상비,동보방화료가능제고만기비인암환자적생존솔,강저원처전이솔.
Objective To determine the value of concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma from the mainland of China. Methods Data were extracted from randomized trials comparing chemotherapy plus radiotherapy with radiotherapy alone in locally advanced nasopharyngeal carcinoma. Actuarial rates of survival and distant metastases were calculated. The followed electronic databases were searched the Chinese Biomedicine database,Pubmed,Medline,Embase and Cochrane library:Data were extracted by tow reviewers and Review manager 4.1 software was applied for statistical analysis. Results Eighteen trials with 1993 patients were include according to the including criterion. The 3-year overall survival rate of the chemoradiotherapy group and the radiotherapy group were 68.47% and 56.38% respectively, and the 5-year overall survival rate of the two groups above were 51.91% and 41.09% respectively, while the distant metastases rate of the chemoradiotherapy group and the radiotherapy group were 26.19% and 38.71% respectively. The result demonstrated that chemoradiotherapy increased overall survival by 12% at 3 years, and 11% at 5 years after treatment. After chemoradiotherapy,the rate of distant metastasis was reduce by 12%. Conclusions In patients with locoregionally advanced nasopharyngeal carcinoma,chemoradiotherapy significantly improves overall survival at 3 years,and 5 years compared with radiotherapy alone.
